Market research
0IF.F LogicBio Therapeutics, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 66M
- P/E ratio
- Not available
- Analyst target
- 18.8
- Dividend yield
- 0.0%
- Beta
- 4.62
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 66M
- P/E ratio
- Not available
- Analyst target
- 18.8
- Dividend yield
- 0.0%
- Beta
- 4.62
About
About LogicBio Therapeutics, Inc
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0IF.F discussion.
5 years, 5 months ago
LogicBio Therapeutics, Inc is currently in a long term downtrend where the price is trading 37.4% below its 200 day moving average.
From a valuation standpoint, the stock is 96.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 53.0.
LogicBio Therapeutics, Inc's total revenue rose by inf% to $542K since the same quarter in the previous year.
Its net income has increased by 39.8% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.7% to $-8M since the same quarter in the previous year.
Based on the above factors, LogicBio Therapeutics, Inc gets an overall score of 4/5.